ES2902006T3 - Quinazolina y compuestos indol para tratar trastornos médicos - Google Patents

Quinazolina y compuestos indol para tratar trastornos médicos Download PDF

Info

Publication number
ES2902006T3
ES2902006T3 ES17821106T ES17821106T ES2902006T3 ES 2902006 T3 ES2902006 T3 ES 2902006T3 ES 17821106 T ES17821106 T ES 17821106T ES 17821106 T ES17821106 T ES 17821106T ES 2902006 T3 ES2902006 T3 ES 2902006T3
Authority
ES
Spain
Prior art keywords
compound
salt
active compound
entitled
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17821106T
Other languages
English (en)
Spanish (es)
Inventor
Jason Allan Wiles
Avinash Phadke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achillion Pharmaceuticals Inc
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2902006T3 publication Critical patent/ES2902006T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3834—Aromatic acids (P-C aromatic linkage)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES17821106T 2016-06-27 2017-06-27 Quinazolina y compuestos indol para tratar trastornos médicos Active ES2902006T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355273P 2016-06-27 2016-06-27
US201762471799P 2017-03-15 2017-03-15
PCT/US2017/039587 WO2018005552A1 (en) 2016-06-27 2017-06-27 Quinazoline and indole compounds to treat medical disorders

Publications (1)

Publication Number Publication Date
ES2902006T3 true ES2902006T3 (es) 2022-03-24

Family

ID=60787571

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17821106T Active ES2902006T3 (es) 2016-06-27 2017-06-27 Quinazolina y compuestos indol para tratar trastornos médicos

Country Status (13)

Country Link
US (3) US10961252B2 (https=)
EP (2) EP3939591A1 (https=)
JP (2) JP7057290B2 (https=)
KR (1) KR20190036520A (https=)
CN (1) CN109414441A (https=)
AU (1) AU2017290593A1 (https=)
CA (1) CA3029262A1 (https=)
ES (1) ES2902006T3 (https=)
IL (1) IL263783A (https=)
MX (1) MX2018016046A (https=)
RU (1) RU2018145364A (https=)
SG (1) SG11201811491YA (https=)
WO (1) WO2018005552A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
RU2018145364A (ru) * 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
BR112021005506A2 (pt) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. formas mórficas de inibidores de fator complementar d
KR20210104071A (ko) 2018-12-17 2021-08-24 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 표적 투약
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2021108447A1 (en) * 2019-11-26 2021-06-03 Omeros Corporation Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant
WO2021168320A1 (en) * 2020-02-20 2021-08-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
US20210335448A1 (en) * 2020-04-27 2021-10-28 Advaita Corporation Methods of identifying treatments using differentially expressed genes
CN114057758A (zh) 2020-08-07 2022-02-18 上海美悦生物科技发展有限公司 补体因子b抑制剂及其药物组合物、制备方法和用途
EP4194449A4 (en) * 2020-08-07 2024-03-20 Shanghai Meiyue Biotech Development Co., Ltd. Heterocyclic compound, preparation method therefor and use thereof
WO2022143940A1 (zh) * 2020-12-30 2022-07-07 南京明德新药研发有限公司 一系列哌啶取代的苯酸类化合物及其应用
CN112940825B (zh) * 2021-02-06 2022-05-13 中国科学院兰州化学物理研究所 磷化硅量子点作为润滑油添加剂的应用、一种润滑油及其制备方法和应用
US20240217953A1 (en) * 2021-04-16 2024-07-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic substituted aromatic carboxylic acid compounds
US20240287034A1 (en) * 2021-06-03 2024-08-29 Chinook Therapeutics, Inc. Substituted indole compounds and methods of use thereof
US20240360103A1 (en) * 2021-06-30 2024-10-31 Apellis Pharmaceuticals, Inc. Complement inhibition
JP2024532847A (ja) 2021-08-18 2024-09-10 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド ベンズアゼピン芳香環誘導体及びその医薬的な応用
US20250243186A1 (en) * 2021-10-27 2025-07-31 Hansoh Bio Llc Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
CA3242815A1 (en) * 2022-01-26 2023-08-03 Shanghai Meiyue Biotech Development Co., Ltd. Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
CN114921071B (zh) * 2022-03-13 2023-07-14 宁波大学 一种抗菌纳米纤维素/phbv复合材料及其制备方法
WO2023237041A1 (zh) * 2022-06-10 2023-12-14 正大天晴药业集团股份有限公司 双环取代的芳香羧酸酯类化合物
CN119698414A (zh) * 2022-06-20 2025-03-25 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
JP7849520B2 (ja) * 2022-06-30 2026-04-21 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 含窒素架橋複素環誘導体の薬学的に許容される塩、結晶形及びその調製方法
WO2024017299A1 (zh) * 2022-07-20 2024-01-25 正大天晴药业集团股份有限公司 一种桥杂环取代的苯酸衍生物或其盐的结晶及其制备方法
CA3266935A1 (en) * 2022-09-10 2024-03-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Piperidine derivatives substituted at position 2, their preparation methods and medicinal uses
EP4617266A1 (en) 2022-11-11 2025-09-17 Shanghai Yisheng Biopharmaceutical company Limited Piperidine-substituted benzoic acid compound, and pharmaceutical composition and use thereof
CN120731075A (zh) * 2023-02-22 2025-09-30 海思科医药集团股份有限公司 一种苯并氮杂芳环衍生物的药物组合物及其在医药上的应用
WO2024193575A1 (zh) * 2023-03-21 2024-09-26 上海美悦生物科技发展有限公司 螺环类化合物及其药物组合物、制备方法和用途
CN119371402A (zh) * 2023-07-26 2025-01-28 上海美悦生物科技发展有限公司 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
WO2025119266A1 (zh) * 2023-12-05 2025-06-12 西藏海思科制药有限公司 苯并氮杂芳环衍生物在治疗补体因子b介导的疾病中的用途
CN120583950A (zh) * 2023-12-29 2025-09-02 艾威药业公司 含二氟泼尼酯的水性纳米胶束眼用制剂
WO2025160045A1 (en) * 2024-01-24 2025-07-31 Lifemine Therapeutics, Inc. N-heterocyclic compounds and methods of use thereof
CN121532400A (zh) * 2024-05-11 2026-02-13 礼邦医药(香港)有限公司 补体因子b抑制剂
WO2026002007A1 (zh) * 2024-06-25 2026-01-02 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB929406A (en) 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5759830A (en) 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5110927A (en) 1987-12-31 1992-05-05 The United States Of America As Represented By The Department Of Health And Human Services Prazosin analog with increased selectivity and duration of action
JP2528706B2 (ja) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5013557A (en) 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
TW209174B (https=) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
SE9401109D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
IT1271679B (it) 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
DE69531957T2 (de) 1994-12-19 2004-08-12 Daiichi Pharmaceutical Co., Ltd. Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6254889B1 (en) 1995-07-26 2001-07-03 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
US5747490A (en) 1995-09-29 1998-05-05 Merck & Co., Inc. Alpha 1b adrenergic receptor antagonists
JPH11512710A (ja) 1995-09-29 1999-11-02 メルク エンド カンパニー インコーポレーテッド アルファ１ｂアドレナリンレセプターアンタゴニスト
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
AU7626496A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Heteroaryl compounds
NZ325248A (en) 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
US6497903B1 (en) 1996-07-01 2002-12-24 Wilhelmus Everhardus Hennink Hydrolysable hydrogels for controlled release
US6395302B1 (en) 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
US6653340B1 (en) 1997-06-03 2003-11-25 Biocryst Pharmaceuticals, Inc. Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
JPH1123485A (ja) 1997-07-07 1999-01-29 Tani Denki Kogyo Kk 基板検査方法及び基板検査装置
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
EP1072263A4 (en) 1998-03-26 2004-03-31 Japan Tobacco Inc AMID DERIVATIVES AND NOCICEPTINANT AGONISTS
WO2000021559A2 (en) 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
JP2000281660A (ja) 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd キナゾリン誘導体
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
IT1312310B1 (it) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
GB9927011D0 (en) 1999-11-16 2000-01-12 Advanced Phytonics Ltd Method for the production of particles
MXPA02006079A (es) 1999-12-20 2004-08-23 Nicholas J Kerkhof Proceso para producir particulas de nanometro mediante secado por aspersion de lecho fluido.
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
US20020015731A1 (en) 1999-12-23 2002-02-07 Appel Leah E. Hydrogel-Driven Drug Dosage Form
JP4751556B2 (ja) 2000-02-28 2011-08-17 ジーンシーグス， インコーポレイテッド ナノカプセルカプセル化システムおよび方法
WO2001068615A1 (en) 2000-03-13 2001-09-20 Chemrx Advanced Technologies, Inc. Quinazoline synthesis
EP1279406A4 (en) 2000-04-03 2007-10-24 Santen Pharmaceutical Co Ltd TRANSPORTERS AND DRUG DISPENSING SYSTEMS USING THESE
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
PT1296651E (pt) 2000-06-27 2008-02-12 Vectura Ltd Método para fazer partículas para serem usadas numa composição farmacêutica
GB2364919A (en) 2000-07-21 2002-02-13 Cambridge Consultants Inhalers
GB0021024D0 (en) 2000-08-29 2000-10-11 Glaxo Group Ltd Inhalation device
ES2382636T3 (es) 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
EP2168571B1 (en) 2000-11-30 2018-08-22 Vectura Limited Particles for use in a Pharmaceutical Composition
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
MXPA04007428A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US20050009910A1 (en) 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
NZ545484A (en) 2003-09-15 2009-09-25 Vectura Ltd Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
CN1997691B (zh) 2003-09-23 2011-07-20 北卡罗来纳大学查珀尔希尔分校 光固化的全氟聚醚用作微流体器件中的新材料
SE0302665D0 (sv) 2003-10-07 2003-10-07 Astrazeneca Ab Novel Process
WO2005044186A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
DK1704585T3 (en) 2003-12-19 2017-05-22 Univ North Carolina Chapel Hill Methods for preparing isolated micro- and nanostructures using soft lithography or printing lithography
EP1713514B1 (en) 2004-01-28 2021-11-24 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
GB0407627D0 (en) 2004-04-02 2004-05-05 Vectura Ltd Corkscrew pump
JP4926943B2 (ja) 2004-04-13 2012-05-09 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２産生を阻害する二塩
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
PL370285A1 (pl) 2004-09-23 2006-04-03 Glaxosmithkline Pharmaceuticals Spółka Akcyjna Inhalator proszkowy
PT1855652E (pt) 2005-01-28 2016-01-26 Bend Res Inc Secagem de partículas contendo fármacos
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
MX2007016039A (es) 2005-06-17 2008-10-27 Univ North Carolina Metodos, sistemas y materiales de fabricacion de nanoparticulas.
EP1922364A4 (en) 2005-08-09 2010-04-21 Univ North Carolina METHOD AND MATERIALS FOR PRODUCING MICROFLUIDIC DEVICES
US20070071756A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
WO2007056561A2 (en) 2005-11-09 2007-05-18 Liquidia Technologies, Inc. Medical device, materials, and methods
EP1968968A1 (en) 2005-12-21 2008-09-17 PainCeptor Pharma Corp. Compositions and methods for modulating gated ion channels
JP2009521493A (ja) 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
WO2007081876A2 (en) 2006-01-04 2007-07-19 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
US8663674B2 (en) 2006-01-13 2014-03-04 Surmodics, Inc. Microparticle containing matrices for drug delivery
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
WO2007133808A2 (en) 2006-05-15 2007-11-22 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
US20100016293A1 (en) 2006-07-03 2010-01-21 Rogier Adriaan Smits Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
US8465775B2 (en) 2006-07-27 2013-06-18 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
GB0617480D0 (en) 2006-09-06 2006-10-18 Univ Sheffield Novel nanoparticles
DE602007012559D1 (de) 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
US9022970B2 (en) 2006-10-16 2015-05-05 Alcon Research, Ltd. Ophthalmic injection device including dosage control device
TWI409081B (zh) 2006-11-09 2013-09-21 Alcon Res Ltd 用於藥物輸送之水不溶性聚合物基質
WO2008100304A2 (en) 2006-11-15 2008-08-21 The University Of North Carolina At Chapel Hill Polymer particle composite having high fidelity order, size, and shape particles
CA2678774A1 (en) 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009145842A2 (en) 2008-04-04 2009-12-03 Forsight Labs, Llc Therapeutic device for pain management and vision
CN102112118A (zh) 2008-04-25 2011-06-29 北卡罗来纳-查佩尔山大学 特别用于非湿润模型的颗粒复制的可降解化合物及其使用方法
WO2009132206A1 (en) 2008-04-25 2009-10-29 Liquidia Technologies, Inc. Compositions and methods for intracellular delivery and release of cargo
EP2133334A1 (en) 2008-06-09 2009-12-16 DAC S.r.l. Heterocyclic derivatives as HDAC inhibitors
WO2010009087A1 (en) 2008-07-15 2010-01-21 Eyegate Pharmaceuticals, Inc. Iontophoretic delivery of a controlled-release formulation in the eye
KR20110074766A (ko) 2008-10-08 2011-07-01 아스트라제네카 아베 흡입 장치 및 의약 분배 방법
US8444907B2 (en) 2008-12-05 2013-05-21 Liquidia Technologies, Inc. Method for producing patterned materials
CA2750140C (en) 2008-12-30 2015-10-06 Hill's Pet Nutrition, Inc. Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US20120052041A1 (en) 2009-02-04 2012-03-01 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
EP2395930A4 (en) 2009-02-10 2013-04-10 Psivida Inc EYE TROWART ASSEMBLY
EP2396316B1 (en) * 2009-02-10 2015-07-01 Janssen Pharmaceutica, N.V. Quinazolinones as prolyl hydroxylase inhibitors
PL2401027T3 (pl) 2009-02-26 2018-04-30 The University Of North Carolina At Chapel Hill Układ do interwencyjnego dostarczania leku
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
US20120114554A1 (en) 2009-07-13 2012-05-10 Liquidia Technologies, Inc. Engineered Aerosol Particles, And Associated Methods
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
WO2011050327A1 (en) 2009-10-23 2011-04-28 Forsight Labs Llc Corneal denervation for treatment of ocular pain
US9498385B2 (en) 2009-10-23 2016-11-22 Nexisvision, Inc. Conformable therapeutic shield for vision and pain
TWI478730B (zh) 2009-12-03 2015-04-01 Alcon Res Ltd 眼科乳劑
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
US20130071349A1 (en) 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
JP5794744B2 (ja) 2010-05-05 2015-10-14 アルコン リサーチ， リミテッド 安定化された眼用ガラクトマンナン処方物
WO2011153349A1 (en) 2010-06-02 2011-12-08 Alcon Research, Ltd. Ophthalmic compositions comprising pbo-peo-pbo block copolymers
SI2600812T1 (sl) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
US20130274692A1 (en) 2010-08-05 2013-10-17 Yair Alster Subconjuctival implant for posterior segment drug delivery
JP6111194B2 (ja) 2010-08-05 2017-04-05 フォーサイト・ビジョン フォー・インコーポレーテッド 組み合わせ薬物送達方法および装置
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012061703A1 (en) 2010-11-05 2012-05-10 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012065006A2 (en) 2010-11-11 2012-05-18 Forsight Vision4, Inc. Methods and apparatus to determine porous structures for drug delivery
TW201304822A (zh) 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2661433B1 (en) 2011-01-04 2017-08-16 Novartis AG Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
WO2012145801A1 (en) 2011-04-29 2012-11-01 Jagat Rakesh Kanwar Nanoparticle
US9228003B2 (en) 2011-05-05 2016-01-05 Wellstat Immuno Therapeutics, Llc Complement factor B analogs and their uses
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
CN103703490B (zh) 2011-06-29 2016-03-30 日本电气方案创新株式会社 用于产生三维特征数据的设备以及用于产生三维特征数据的方法
EP2540640A3 (en) 2011-06-29 2013-03-20 Rehrig Pacific Company Crate with retractable wall
EP2755615B1 (en) 2011-09-14 2022-04-06 Forsight Vision5, Inc. Ocular insert apparatus
GB201115874D0 (en) 2011-09-14 2011-10-26 Astrazeneca Ab Inhaler
RS61758B1 (sr) 2011-09-16 2021-05-31 Forsight Vision4 Inc Aparati za razmenu tečnosti
US20150037428A1 (en) 2011-11-29 2015-02-05 The University Of North Carolina At Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
US20140329913A1 (en) 2011-12-14 2014-11-06 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
CN102516232A (zh) 2011-12-14 2012-06-27 无锡美克赛医药科技有限公司 一种ErbB2的小分子选择性抑制剂及其应用
PT2797652T (pt) 2011-12-27 2019-02-19 Vectura Gmbh Dispositivo para inalação com sistema de feedback
CA2863632C (en) 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
CN104271187B (zh) 2012-03-09 2018-01-12 维克多瑞有限责任公司 吸入装置的混合通道与吸入装置
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
KR102310775B1 (ko) 2012-05-03 2021-10-07 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256064B2 (en) 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
EP2855456B1 (en) 2012-05-04 2017-03-29 Novartis AG Complement pathway modulators and uses thereof
JP6163205B2 (ja) 2012-06-20 2017-07-12 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
JP6214647B2 (ja) 2012-06-28 2017-10-18 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
EP2867222A1 (en) 2012-06-28 2015-05-06 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
WO2014002059A1 (en) 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
WO2014005150A1 (en) 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
WO2014009833A2 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
ES1077714Y (es) 2012-07-31 2012-12-20 Gutierrez Jose Ramon Perez Envase de madera
WO2014035876A1 (en) 2012-08-27 2014-03-06 William Marsh Rice University Heat-inactivated complement factor b compositions and methods
BR112015005878A2 (pt) 2012-09-17 2017-07-04 Bind Therapeutics Inc nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
JP2015532928A (ja) 2012-09-20 2015-11-16 アキナ， インク．Ａｋｉｎａ， Ｉｎｃ． 充填材料を含有する生体分解可能なマイクロカプセル
DK2911623T3 (da) 2012-10-26 2019-10-28 Forsight Vision5 Inc Oftalmisk system til langvarig frigivelse af lægemiddel til øjet
PL2724741T3 (pl) 2012-10-26 2017-11-30 Vectura Gmbh Urządzenie inhalacyjne do stosowania w terapii aerozolowej
EP2970269B1 (en) 2013-03-14 2017-04-19 Novartis AG 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
CA2905496A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
EA201690247A1 (ru) 2013-07-18 2016-06-30 Новартис Аг Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
DK3043827T3 (da) 2013-09-13 2019-08-26 Ionis Pharmaceuticals Inc Modulatorer af komplement faktor b
CA2927321A1 (en) 2013-10-15 2015-04-23 Forsight Vision5, Inc. Formulations and methods for increasing or reducing mucus
EP3089963A1 (en) 2013-10-30 2016-11-09 Novartis AG 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
MX2016007345A (es) 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
WO2015085234A1 (en) 2013-12-06 2015-06-11 Forsight Vision4, Inc. Implantable therapeutic devices
RU2018145364A (ru) * 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений

Also Published As

Publication number Publication date
SG11201811491YA (en) 2019-01-30
IL263783A (en) 2019-01-31
EP3448389A4 (en) 2019-10-30
JP2019527203A (ja) 2019-09-26
MX2018016046A (es) 2019-05-02
US11248000B2 (en) 2022-02-15
CN109414441A (zh) 2019-03-01
EP3448389A1 (en) 2019-03-06
JP2022091984A (ja) 2022-06-21
US20200165262A1 (en) 2020-05-28
CA3029262A1 (en) 2018-01-04
RU2018145364A (ru) 2020-07-28
EP3448389B1 (en) 2021-09-29
US20220119400A1 (en) 2022-04-21
US10961252B2 (en) 2021-03-30
JP7057290B2 (ja) 2022-04-19
US20190135825A1 (en) 2019-05-09
AU2017290593A1 (en) 2019-01-03
WO2018005552A1 (en) 2018-01-04
EP3939591A1 (en) 2022-01-19
KR20190036520A (ko) 2019-04-04

Similar Documents

Publication Publication Date Title
ES2902006T3 (es) Quinazolina y compuestos indol para tratar trastornos médicos
US12338230B2 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US11649229B2 (en) Amide compounds for treatment of immune and inflammatory disorders
US11649223B2 (en) Amino compounds for treatment of immune and inflammatory disorders
US11001600B2 (en) Disubstituted compounds for treatment of medical disorders
ES3040193T3 (en) Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US10385097B2 (en) Ether compounds for treatment of medical disorders
US10660876B2 (en) Amino compounds for treatment of medical disorders
US10138225B2 (en) Amide compounds for treatment of medical disorders
US10000516B2 (en) Phosphonate compounds for treatment of medical disorders
EP3340982B1 (en) Compounds for treatment of immune and inflammatory disorders
WO2017035418A1 (en) Disubstituted compounds for treatment of immune and inflammatory disorders
WO2017035415A1 (en) Alkyne compounds for treatment of immune and inflammatory disorders
WO2017035413A2 (en) Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
WO2017035352A1 (en) Carbamate, ester, and ketone compounds for treatment of medical disorders
WO2017035417A1 (en) Phosphonate compounds for treatment of immune and inflammatory disorders
WO2017035348A1 (en) Alkyne compounds for treatment of medical disorders